The IL-23/IL-17 pathway in inflammatory bowel disease

References

• Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology126(6), 1504–1517 (2004).
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol. Clin. N. Am.31(1), 1–20 (2002).
   PubMed Web of Science ®Google Scholar
• Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res.29(7), 2727–2737 (2009).
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am. J. Gastroenterol.96(4), 1116–1122 (2001).
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: apopulation-based study. Gastroenterology129(3), 827–836 (2005).
   PubMed Web of Science ®Google Scholar
• Abraham C, Cho JH. Inflammatory bowel disease. N. Engl. J. Med.361(21), 2066–2078 (2009).
   PubMed Web of Science ®Google Scholar
• Fuss IJ, Neurath M, Boirivant M et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol.157(3), 1261–1270 (1996).
   PubMed Web of Science ®Google Scholar
• Monteleone G, Biancone L, Marasco R et al. Interleukin 12 is expressed and actively released by Crohn’s disease intestinal lamina propria mononuclear cells. Gastroenterology112(4), 1169–1178 (1997).
   PubMed Web of Science ®Google Scholar
• Parronchi P, Romagnani P, Annunziato F et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn’s disease. Am. J. Pathol.150(3), 823–832 (1997).
   PubMed Web of Science ®Google Scholar
• Heller F, Florian P, Bojarski C et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology129(2), 550–564 (2005).
   PubMed Web of Science ®Google Scholar
• Niessner M, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin. Exp. Immunol.101(3), 428–435 (1995).
   PubMed Web of Science ®Google Scholar
• Lee TW, Fedorak RN. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. Gastroenterol. Clin. N. Am.39(3), 543–557 (2010).
   PubMed Web of Science ®Google Scholar
• Mannon PJ, Fuss IJ, Mayer L et al. Anti-interleukin-12 antibody for active Crohn’s disease. N. Engl. J. Med.351(20), 2069–2079 (2004).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Fedorak RN et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology135(4), 1130–1141 (2008).
   PubMed Web of Science ®Google Scholar
• Toedter GP, Blank M, Lang Y, Chen D, Sandborn WJ, de Villiers WJ. Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn’s disease. Am. J. Gastroenterol.104(11), 2768–2773 (2009).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Gasink C, Gao L et al. A multicenter, randomized, double-blind, placebo-controlled, Phase 2b study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately to severely active Crohn’s disease: results through week 22 from the Certifi trial. Gastroenterology140(5 Suppl. 1), S109 (2012).
   Google Scholar
• Cua DJ, Sherlock J, Chen Y et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature421(6924), 744–748 (2003).
   PubMed Web of Science ®Google Scholar
• Murphy CA, Langrish CL, Chen Y et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med.198(12), 1951–1957 (2003).
   PubMed Web of Science ®Google Scholar
• Zheng Y, Danilenko DM, Valdez P et al. Interleukin-22, a T(h)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature445(7128), 648–651 (2007).
   PubMed Web of Science ®Google Scholar
• Yen D, Cheung J, Scheerens H et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest.116(5), 1310–1316 (2006).
   PubMed Web of Science ®Google Scholar
• Uhlig HH, McKenzie BS, Hue S et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity25(2), 309–318 (2006).
   PubMed Web of Science ®Google Scholar
• Hue S, Ahern P, Buonocore S et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med.203(11), 2473–2483 (2006).
   PubMed Web of Science ®Google Scholar
• Kullberg MC, Jankovic D, Feng CG et al. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J. Exp. Med.203(11), 2485–2494 (2006).
   PubMed Web of Science ®Google Scholar
• Elson CO, Cong Y, Weaver CT et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology132(7), 2359–2370 (2007).
   PubMed Web of Science ®Google Scholar
• Li Y, Chu N, Hu A, Gran B, Rostami A, Zhang GX. Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. Brain130(Pt 2), 490–501 (2007).
   PubMed Web of Science ®Google Scholar
• Lee E, Trepicchio WL, Oestreicher JL et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med.199(1), 125–130 (2004).
   PubMed Web of Science ®Google Scholar
• Kim HR, Cho ML, Kim KW et al. Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF-κB- and p38 MAPK-dependent signalling pathways. Rheumatology (Oxford)46(1), 57–64 (2007).
   PubMed Web of Science ®Google Scholar
• Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev.202, 96–105 (2004).
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol.3(2), 133–146 (2003).
   PubMed Web of Science ®Google Scholar
• Willenborg DO, Fordham S, Bernard CC, Cowden WB, Ramshaw IA. IFN-γ plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J. Immunol.157(8), 3223–3227 (1996).
   PubMed Web of Science ®Google Scholar
• Krakowski M, Owens T. Interferon-γ confers resistance to experimental allergic encephalomyelitis. Eur. J. Immunol.26(7), 1641–1646 (1996).
   PubMed Web of Science ®Google Scholar
• Duong TT, St Louis J, Gilbert JJ, Finkelman FD, Strejan GH. Effect of anti-interferon-γ and anti-interleukin-2 monoclonal antibody treatment on the development of actively and passively induced experimental allergic encephalomyelitis in the SJL/J mouse. J. Neuroimmunol.36(2–3), 105–115 (1992).
   PubMed Web of Science ®Google Scholar
• Billiau A, Heremans H, Vandekerckhove F et al. Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-γ. J. Immunol.140(5), 1506–1510 (1988).
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity13(5), 715–725 (2000).
   PubMed Web of Science ®Google Scholar
• Stallmach A, Giese T, Schmidt C, Ludwig B, Mueller-Molaian I, Meuer SC. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn’s disease. Int. J. Colorectal. Dis.19(4), 308–315 (2004).
   PubMedGoogle Scholar
• LeibundGut-Landmann S, Gross O, Robinson MJ et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat. Immunol.8(6), 630–638 (2007).
   PubMed Web of Science ®Google Scholar
• Re F, Strominger JL. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J. Biol. Chem.276(40), 37692–37699 (2001).
   PubMed Web of Science ®Google Scholar
• van Beelen AJ, Zelinkova Z, Taanman-Kueter EW et al. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity27(4), 660–669 (2007).
   PubMed Web of Science ®Google Scholar
• Sheibanie AF, Tadmori I, Jing H, Vassiliou E, Ganea D. Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells. FASEB J.18(11), 1318–1320 (2004).
   PubMedGoogle Scholar
• Parham C, Chirica M, Timans J et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J. Immunol.168(11), 5699–5708 (2002).
   PubMed Web of Science ®Google Scholar
• Awasthi A, Riol-Blanco L, Jager A et al. Cutting edge: IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-producing cells. J. Immunol.182(10), 5904–5908 (2009).
   PubMed Web of Science ®Google Scholar
• Buonocore S, Ahern PP, Uhlig HH et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature464(7293), 1371–1375 (2010).
   PubMed Web of Science ®Google Scholar
• Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J. Infect. Dis.190(3), 624–631 (2004).
   PubMed Web of Science ®Google Scholar
• Mangan PR, Harrington LE, O’Quinn DB et al. Transforming growth factor-β induces development of the T(h)17 lineage. Nature441(7090), 231–234 (2006).
   PubMed Web of Science ®Google Scholar
• Ye P, Garvey PB, Zhang P et al. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am. J. Respir. Cell. Mol. Biol.25(3), 335–340 (2001).
   PubMed Web of Science ®Google Scholar
• Khader SA, Bell GK, Pearl JE et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol.8(4), 369–377 (2007).
   PubMed Web of Science ®Google Scholar
• Langrish CL, Chen Y, Blumenschein WM et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med.201(2), 233–240 (2005).
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu. Rev. Immunol.27, 485–517 (2009).
   PubMed Web of Science ®Google Scholar
• Stritesky GL, Yeh N, Kaplan MH. IL-23 promotes maintenance but not commitment to the Th17 lineage. J. Immunol.181(9), 5948–5955 (2008).
   PubMed Web of Science ®Google Scholar
• McGeachy MJ, Chen Y, Tato CM et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat. Immunol.10(3), 314–324 (2009).
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity24(2), 179–189 (2006).
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W et al. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature441(7090), 235–238 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou L, Ivanov II, Spolski R et al. IL-6 programs T(h)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol.8(9), 967–974 (2007).
   PubMed Web of Science ®Google Scholar
• Nurieva R, Yang XO, Martinez G et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature448(7152), 480–483 (2007).
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Gao W et al. IL-21 initiates an alternative pathway to induce proinflammatory T(h)17 cells. Nature448(7152), 484–487 (2007).
   PubMed Web of Science ®Google Scholar
• Chung Y, Chang SH, Martinez GJ et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity30(4), 576–587 (2009).
   PubMed Web of Science ®Google Scholar
• Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med.203(7), 1685–1691 (2006).
   PubMed Web of Science ®Google Scholar
• Ivanov II, McKenzie BS, Zhou L et al. The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell126(6), 1121–1133 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang F, Meng G, Strober W. Interactions among the transcription factors Runx1, RORγt and Foxp3 regulate the differentiation of interleukin 17-producing T cells. Nat. Immunol.9(11), 1297–1306 (2008).
   PubMed Web of Science ®Google Scholar
• Yang XO, Pappu BP, Nurieva R et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR α and ROR γ. Immunity28(1), 29–39 (2008).
   PubMed Web of Science ®Google Scholar
• Kimura A, Naka T, Nohara K, Fujii-Kuriyama Y, Kishimoto T. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc. Natl Acad. Sci. USA105(28), 9721–9726 (2008).
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Hirota K, Westendorf AM et al. The aryl hydrocarbon receptor links Th17-cell-mediated autoimmunity to environmental toxins. Nature453(7191), 106–109 (2008).
   PubMed Web of Science ®Google Scholar
• Huber M, Brustle A, Reinhard K et al. IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype. Proc. Natl Acad. Sci. USA105(52), 20846–20851 (2008).
   PubMed Web of Science ®Google Scholar
• Harris TJ, Grosso JF, Yen HR et al. Cutting edge: an in vivo requirement for STAT3 signaling in Th17 development and TH17-dependent autoimmunity. J. Immunol.179(7), 4313–4317 (2007).
   PubMed Web of Science ®Google Scholar
• Bauquet AT, Jin H, Paterson AM et al. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and Th-17 cells. Nat. Immunol.10(2), 167–175 (2009).
   PubMed Web of Science ®Google Scholar
• Park H, Li Z, Yang XO et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol.6(11), 1133–1141 (2005).
   PubMed Web of Science ®Google Scholar
• Nakae S, Iwakura Y, Suto H, Galli SJ. Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J. Leukoc. Biol.81(5), 1258–1268 (2007).
   PubMed Web of Science ®Google Scholar
• Zheng SG, Gray JD, Ohtsuka K, Yamagiwa S, Horwitz DA. Generation ex vivo of TGF-β-producing regulatory T cells from CD4+CD25- precursors. J. Immunol.169(8), 4183–4189 (2002).
   PubMed Web of Science ®Google Scholar
• Chen W, Jin W, Hardegen N et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med.198(12), 1875–1886 (2003).
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, Yang XP et al. Generation of pathogenic T(h)17 cells in the absence of TGF-β signalling. Nature467(7318), 967–971 (2010).
   PubMed Web of Science ®Google Scholar
• Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol.8(9), 942–949 (2007).
   PubMed Web of Science ®Google Scholar
• Wilson NJ, Boniface K, Chan JR et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol.8(9), 950–957 (2007).
   PubMed Web of Science ®Google Scholar
• Manel N, Unutmaz D, Littman DR. The differentiation of human T(h)-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt. Nat. Immunol.9(6), 641–649 (2008).
   PubMed Web of Science ®Google Scholar
• Volpe E, Servant N, Zollinger R et al. A critical function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving and modulating human T(h)-17 responses. Nat. Immunol.9(6), 650–657 (2008).
   PubMed Web of Science ®Google Scholar
• Yang L, Anderson DE, Baecher-Allan C et al. IL-21 and TGF-β are required for differentiation of human T(h)17 cells. Nature454(7202), 350–352 (2008).
   PubMed Web of Science ®Google Scholar
• Cosmi L, De Palma R, Santarlasci V et al. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J. Exp. Med.205(8), 1903–1916 (2008).
   PubMed Web of Science ®Google Scholar
• Kleinschek MA, Boniface K, Sadekova S et al. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J. Exp. Med.206(3), 525–534 (2009).
   PubMed Web of Science ®Google Scholar
• Acosta-Rodriguez EV, Rivino L, Geginat J et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol.8(6), 639–646 (2007).
   PubMed Web of Science ®Google Scholar
• Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat. Rev. Immunol.10(7), 479–489 (2010).
   PubMed Web of Science ®Google Scholar
• Chua WJ, Hansen TH. Bacteria, mucosal-associated invariant T cells and MR1. Immunol. Cell Biol.88(8), 767–769 (2010).
   PubMedGoogle Scholar
• Lochner M, Peduto L, Cherrier M et al.In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORγ t+ T cells. J. Exp. Med.205(6), 1381–1393 (2008).
   PubMed Web of Science ®Google Scholar
• Martin B, Hirota K, Cua DJ, Stockinger B, Veldhoen M. Interleukin-17-producing γδ T cells selectively expand in response to pathogen products and environmental signals. Immunity31(2), 321–330 (2009).
   PubMed Web of Science ®Google Scholar
• Roark CL, French JD, Taylor MA, Bendele AM, Born WK, O’Brien RL. Exacerbation of collagen-induced arthritis by oligoclonal, IL-17-producing γδ T cells. J. Immunol.179(8), 5576–5583 (2007).
   PubMed Web of Science ®Google Scholar
• Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH. Interleukin-1 and IL-23 induce innate IL-17 production from γδ T cells, amplifying Th17 responses and autoimmunity. Immunity31(2), 331–341 (2009).
   PubMed Web of Science ®Google Scholar
• Ito Y, Usui T, Kobayashi S et al. γδ T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis. Arthritis Rheum.60(8), 2294–2303 (2009).
   PubMed Web of Science ®Google Scholar
• Ness-Schwickerath KJ, Jin C, Morita CT. Cytokine requirements for the differentiation and expansion of IL-17A- and IL-22-producing human Vγ2Vδ2 T cells. J. Immunol.184(12), 7268–7280 (2010).
   PubMed Web of Science ®Google Scholar
• Michel ML, Keller AC, Paget C et al. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J. Exp. Med.204(5), 995–1001 (2007).
   PubMed Web of Science ®Google Scholar
• Rachitskaya AV, Hansen AM, Horai R et al. Cutting edge: NKT cells constitutively express IL-23 receptor and RORγt and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J. Immunol.180(8), 5167–5171 (2008).
   PubMed Web of Science ®Google Scholar
• Dusseaux M, Martin E, Serriari N et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood117(4), 1250–1259 (2011).
   PubMed Web of Science ®Google Scholar
• Northfield JW, Kasprowicz V, Lucas M et al. CD161 expression on hepatitis C virus-specific CD8+ T cells suggests a distinct pathway of T cell differentiation. Hepatology47(2), 396–406 (2008).
   PubMed Web of Science ®Google Scholar
• Billerbeck E, Kang YH, Walker L et al. Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. Proc. Natl Acad. Sci. USA107(7), 3006–3011 (2010).
   PubMed Web of Science ®Google Scholar
• Takatori H, Kanno Y, Watford WT et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J. Exp. Med.206(1), 35–41 (2009).
   PubMed Web of Science ®Google Scholar
• Vondenhoff MF, Kraal G, Mebius RE. Lymphoid organogenesis in brief. Eur. J. Immunol.37(Suppl. 1), S46–S52 (2007).
   Google Scholar
• Mebius RE, Rennert P, Weissman IL. Developing lymph nodes collect CD4+CD3- LTβ+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells. Immunity7(4), 493–504 (1997).
   PubMed Web of Science ®Google Scholar
• Randall TD, Carragher DM, Rangel-Moreno J. Development of secondary lymphoid organs. Annu. Rev. Immunol.26, 627–650 (2008).
   PubMed Web of Science ®Google Scholar
• Cupedo T, Crellin NK, Papazian N et al. Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat. Immunol.10(1), 66–74 (2009).
   PubMed Web of Science ®Google Scholar
• Schmutz S, Bosco N, Chappaz S et al. Cutting edge: IL-7 regulates the peripheral pool of adult RORγ+ lymphoid tissue inducer cells. J. Immunol.183(4), 2217–2221 (2009).
   PubMed Web of Science ®Google Scholar
• Cella M, Fuchs A, Vermi W et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature457(7230), 722–725 (2009).
   PubMed Web of Science ®Google Scholar
• Crellin NK, Trifari S, Kaplan CD, Cupedo T, Spits H. Human NKp44+IL-22+ cells and LTi-like cells constitute a stable RORC+ lineage distinct from conventional natural killer cells. J. Exp. Med.207(2), 281–290 (2010).
   PubMed Web of Science ®Google Scholar
• Satoh-Takayama N, Lesjean-Pottier S, Vieira P et al. IL-7 and IL-15 independently program the differentiation of intestinal CD3-NKp46+ cell subsets from Id2-dependent precursors. J. Exp. Med.207(2), 273–280 (2010).
   PubMedGoogle Scholar
• Crellin NK, Trifari S, Kaplan CD, Satoh-Takayama N, Di Santo JP, Spits H. Regulation of cytokine secretion in human CD127(+) LTi-like innate lymphoid cells by Toll-like receptor 2. Immunity33(5), 752–764 (2010).
   PubMed Web of Science ®Google Scholar
• Moro K, Yamada T, Tanabe M et al. Innate production of T(h)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature463(7280), 540–544 (2009).
   PubMedGoogle Scholar
• Neill DR, Wong SH, Bellosi A et al. Nuocytes represent a new innate effector leukocyte that mediates Type 2 immunity. Nature464(7293), 1367–1370 (2010).
   PubMed Web of Science ®Google Scholar
• Hueber AJ, Asquith DL, Miller AM et al. Mast cells express IL-17A in rheumatoid arthritis synovium. J. Immunol.184(7), 3336–3340 (2010).
   PubMed Web of Science ®Google Scholar
• Li L, Huang L, Vergis AL et al. IL-17 produced by neutrophils regulates IFN-γ-mediated neutrophil migration in mouse kidney ischemia–reperfusion injury. J. Clin. Invest.120(1), 331–342 (2010).
   PubMed Web of Science ®Google Scholar
• Yang XO, Panopoulos AD, Nurieva R et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J. Biol. Chem.282(13), 9358–9363 (2007).
   PubMed Web of Science ®Google Scholar
• Wright JF, Guo Y, Quazi A et al. Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells. J. Biol. Chem.282(18), 13447–13455 (2007).
   PubMed Web of Science ®Google Scholar
• Yao Z, Spriggs MK, Derry JM et al. Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine9(11), 794–800 (1997).
   PubMed Web of Science ®Google Scholar
• Toy D, Kugler D, Wolfson M et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J. Immunol.177(1), 36–39 (2006).
   PubMed Web of Science ®Google Scholar
• Kuestner RE, Taft DW, Haran A et al. Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J. Immunol.179(8), 5462–5473 (2007).
   PubMed Web of Science ®Google Scholar
• Xu S, Cao X. Interleukin-17 and its expanding biological functions. Cell. Mol. Immunol.7(3), 164–174 (2010).
   PubMed Web of Science ®Google Scholar
• Kawaguchi M, Onuchic LF, Li XD et al. Identification of a novel cytokine, ML-1, and its expression in subjects with asthma. J. Immunol.167(8), 4430–4435 (2001).
   PubMed Web of Science ®Google Scholar
• Kawaguchi M, Kokubu F, Odaka M et al. Induction of granulocyte-macrophage colony-stimulating factor by a new cytokine, ML-1 (IL-17F), via Raf I–MEK–ERK pathway. J. Allergy Clin. Immunol.114(2), 444–450 (2004).
   PubMed Web of Science ®Google Scholar
• Yang XO, Chang SH, Park H et al. Regulation of inflammatory responses by IL-17F. J. Exp. Med.205(5), 1063–1075 (2008).
   PubMed Web of Science ®Google Scholar
• Liang SC, Tan XY, Luxenberg DP et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med.203(10), 2271–2279 (2006).
   PubMed Web of Science ®Google Scholar
• Ishigame H, Kakuta S, Nagai T et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity30(1), 108–119 (2009).
   PubMed Web of Science ®Google Scholar
• Schwarzenberger P, Kolls JK. Interleukin 17: an example for gene therapy as a tool to study cytokine mediated regulation of hematopoiesis. J. Cell Biochem. Suppl.38, 88–95 (2002).
   PubMedGoogle Scholar
• Parrish-Novak J, Foster DC, Holly RD, Clegg CH. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J. Leukoc. Biol.72(5), 856–863 (2002).
   PubMed Web of Science ®Google Scholar
• Ozaki K, Kikly K, Michalovich D, Young PR, Leonard WJ. Cloning of a Type 1 cytokine receptor most related to the IL-2 receptor β chain. Proc. Natl Acad. Sci. USA97(21), 11439–11444 (2000).
   PubMed Web of Science ®Google Scholar
• Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu. Rev. Immunol.26, 57–79 (2008).
   PubMed Web of Science ®Google Scholar
• Zeng R, Spolski R, Finkelstein SE et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J. Exp. Med.201(1), 139–148 (2005).
   PubMed Web of Science ®Google Scholar
• Fantini MC, Rizzo A, Fina D et al. IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur. J. Immunol.37(11), 3155–3163 (2007).
   PubMed Web of Science ®Google Scholar
• Peluso I, Fantini MC, Fina D et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J. Immunol.178(2), 732–739 (2007).
   PubMed Web of Science ®Google Scholar
• Strengell M, Matikainen S, Siren J et al. IL-21 in synergy with IL-15 or IL-18 enhances IFN-γ production in human NK and T cells. J. Immunol.170(11), 5464–5469 (2003).
   PubMed Web of Science ®Google Scholar
• Monteleone G, Monteleone I, Fina D et al. Interleukin-21 enhances T-helper cell Type 1 signaling and interferon-γ production in Crohn’s disease. Gastroenterology128(3), 687–694 (2005).
   PubMed Web of Science ®Google Scholar
• Ozaki K, Spolski R, Feng CG et al. A critical role for IL-21 in regulating immunoglobulin production. Science298(5598), 1630–1634 (2002).
   PubMed Web of Science ®Google Scholar
• Wurster AL, Rodgers VL, Satoskar AR et al. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon γ-producing Th1 cells. J. Exp. Med.196(7), 969–977 (2002).
   PubMed Web of Science ®Google Scholar
• Ozaki K, Spolski R, Ettinger R et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J. Immunol.173(9), 5361–5371 (2004).
   PubMed Web of Science ®Google Scholar
• Pene J, Gauchat JF, Lecart S et al. Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells. J. Immunol.172(9), 5154–5157 (2004).
   PubMed Web of Science ®Google Scholar
• Monteleone G, Caruso R, Fina D et al. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut55(12), 1774–1780 (2006).
   PubMed Web of Science ®Google Scholar
• Caruso R, Fina D, Peluso I et al. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3α, by gut epithelial cells. Gastroenterology132(1), 166–175 (2007).
   PubMed Web of Science ®Google Scholar
• King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell117(2), 265–277 (2004).
   PubMed Web of Science ®Google Scholar
• Jin H, Oyoshi MK, Le Y et al. IL-21R is essential for epicutaneous sensitization and allergic skin inflammation in humans and mice. J. Clin. Invest.119(1), 47–60 (2009).
   PubMed Web of Science ®Google Scholar
• Distler JH, Jungel A, Kowal-Bielecka O et al. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum.52(3), 856–864 (2005).
   PubMed Web of Science ®Google Scholar
• Sawalha AH, Kaufman KM, Kelly JA et al. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann. Rheum. Dis.67(4), 458–461 (2008).
   PubMed Web of Science ®Google Scholar
• Fina D, Sarra M, Fantini MC et al. Regulation of gut inflammation and Th17 cell response by interleukin-21. Gastroenterology134(4), 1038–1048 (2008).
   PubMed Web of Science ®Google Scholar
• van Heel DA, Franke L, Hunt KA et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat. Genet.39(7), 827–829 (2007).
   PubMed Web of Science ®Google Scholar
• Glas J, Stallhofer J, Ripke S et al. Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease. Am. J. Gastroenterol.104(7), 1737–1744 (2009).
   PubMedGoogle Scholar
• Stallhofer J, Denk GU, Glas J et al. Analysis of IL2/IL21 gene variants in cholestatic liver diseases reveals an association with primary sclerosing cholangitis. Digestion84(1), 29–35 (2011).
   PubMedGoogle Scholar
• Xie MH, Aggarwal S, Ho WH et al. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J. Biol. Chem.275(40), 31335–31339 (2000).
   PubMed Web of Science ®Google Scholar
• Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity21(2), 241–254 (2004).
   PubMed Web of Science ®Google Scholar
• Wolk K, Witte E, Wallace E et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur. J. Immunol.36(5), 1309–1323 (2006).
   PubMed Web of Science ®Google Scholar
• Wolk K, Haugen HS, Xu W et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not. J. Mol. Med.87(5), 523–536 (2009).
   PubMed Web of Science ®Google Scholar
• Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat. Immunol.10(8), 857–863 (2009).
   PubMed Web of Science ®Google Scholar
• Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(h)-17, T(h)1 and T(h)2 cells. Nat. Immunol.10(8), 864–871 (2009).
   PubMed Web of Science ®Google Scholar
• Zheng Y, Valdez PA, Danilenko DM et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat. Med.14(3), 282–289 (2008).
   PubMed Web of Science ®Google Scholar
• Aujla SJ, Chan YR, Zheng M et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat. Med.14(3), 275–281 (2008).
   PubMed Web of Science ®Google Scholar
• Ma HL, Liang S, Li J et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J. Clin. Invest.118(2), 597–607 (2008).
   PubMed Web of Science ®Google Scholar
• Radaeva S, Sun R, Pan HN, Hong F, Gao B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology39(5), 1332–1342 (2004).
   PubMed Web of Science ®Google Scholar
• Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity27(4), 647–659 (2007).
   PubMed Web of Science ®Google Scholar
• Sugimoto K, Ogawa A, Mizoguchi E et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J. Clin. Invest.118(2), 534–544 (2008).
   PubMed Web of Science ®Google Scholar
• Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Stevens S, Flavell RA. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity29(6), 947–957 (2008).
   PubMed Web of Science ®Google Scholar
• Andoh A, Zhang Z, Inatomi O et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology129(3), 969–984 (2005).
   PubMed Web of Science ®Google Scholar
• Brand S, Beigel F, Olszak T et al. IL-22 is increased in active Crohn’s disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am. J. Physiol. Gastrointest. Liver Physiol.290(4), G827–G838 (2006).
   PubMed Web of Science ®Google Scholar
• Geremia A, Arancibia-Carcamo CV, Fleming MP et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J. Exp. Med.208(6), 1127–1133 (2011).
   PubMed Web of Science ®Google Scholar
• Wolk K, Witte E, Hoffmann U et al. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn’s disease. J. Immunol.178(9), 5973–5981 (2007).
   PubMed Web of Science ®Google Scholar
• Knappe A, Hor S, Wittmann S, Fickenscher H. Induction of a novel cellular homolog of interleukin-10, AK155, by transformation of T lymphocytes with herpesvirus saimiri. J. Virol.74(8), 3881–3887 (2000).
   PubMed Web of Science ®Google Scholar
• Wolk K, Kunz S, Asadullah K, Sabat R. Cutting edge: immune cells as sources and targets of the IL-10 family members? J. Immunol.168(11), 5397–5402 (2002).
   PubMed Web of Science ®Google Scholar
• Sheikh F, Baurin VV, Lewis-Antes A et al. Cutting edge: IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-10 receptor 2. J. Immunol.172(4), 2006–2010 (2004).
   PubMed Web of Science ®Google Scholar
• Hor S, Pirzer H, Dumoutier L et al. The T-cell lymphokine interleukin-26 targets epithelial cells through the interleukin-20 receptor 1 and interleukin-10 receptor 2 chains. J. Biol. Chem.279(32), 33343–33351 (2004).
   PubMed Web of Science ®Google Scholar
• Dambacher J, Beigel F, Zitzmann K et al. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut58(9), 1207–1217 (2009).
   PubMed Web of Science ®Google Scholar
• Maloy KJ, Salaun L, Cahill R, Dougan G, Saunders NJ, Powrie F. CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J. Exp. Med.197(1), 111–119 (2003).
   PubMed Web of Science ®Google Scholar
• Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int. Immunol.5(11), 1461–1471 (1993).
   PubMed Web of Science ®Google Scholar
• Leach MW, Bean AG, Mauze S, Coffman RL, Powrie F. Inflammatory bowel disease in C.B-17 scid mice reconstituted with the CD45RBhigh subset of CD4+ T cells. Am. J. Pathol.148(5), 1503–1515 (1996).
   PubMed Web of Science ®Google Scholar
• Morrissey PJ, Charrier K, Braddy S, Liggitt D, Watson JD. CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immune deficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells. J. Exp. Med.178(1), 237–244 (1993).
   PubMed Web of Science ®Google Scholar
• Izcue A, Hue S, Buonocore S et al. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity28(4), 559–570 (2008).
   PubMed Web of Science ®Google Scholar
• Ahern PP, Schiering C, Buonocore S et al. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity33(2), 279–288 (2010).
   PubMed Web of Science ®Google Scholar
• Leppkes M, Becker C, Ivanov II et al. RORγ-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology136(1), 257–267 (2009).
   PubMed Web of Science ®Google Scholar
• Sonnenberg GF, Monticelli LA, Elloso MM, Fouser LA, Artis D. CD4(+) lymphoid tissue-inducer cells promote innate immunity in the gut. Immunity34(1), 122–134 (2011).
   PubMed Web of Science ®Google Scholar
• Geddes K, Rubino SJ, Magalhaes JG et al. Identification of an innate T helper Type 17 response to intestinal bacterial pathogens. Nat. Med.17(7), 837–844 (2011).
   PubMed Web of Science ®Google Scholar
• Becker C, Dornhoff H, Neufert C et al. Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J. Immunol.177(5), 2760–2764 (2006).
   PubMed Web of Science ®Google Scholar
• Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science314(5804), 1461–1463 (2006).
   PubMed Web of Science ®Google Scholar
• Barrett JC, Hansoul S, Nicolae DL et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat. Genet.40(8), 955–962 (2008).
   PubMed Web of Science ®Google Scholar
• Fisher SA, Tremelling M, Anderson CA et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn’s disease. Nat. Genet.40(6), 710–712 (2008).
   PubMed Web of Science ®Google Scholar
• Franke A, Balschun T, Karlsen TH et al. Replication of signals from recent studies of Crohn’s disease identifies previously unknown disease loci for ulcerative colitis. Nat. Genet.40(6), 713–715 (2008).
   PubMed Web of Science ®Google Scholar
• Anderson CA, Boucher G, Lees CW et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat. Genet.43(3), 246–252 (2011).
   PubMed Web of Science ®Google Scholar
• Di Meglio P, Di Cesare A, Laggner U et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One6(2), e17160 (2011).
   PubMed Web of Science ®Google Scholar
• Pidasheva S, Trifari S, Phillips A et al. Functional studies on the IBD susceptibility gene IL23R implicate reduced receptor function in the protective genetic variant R381Q. PLoS One6(10), e25038 (2011).
   PubMed Web of Science ®Google Scholar
• Sarin R, Wu X, Abraham C. Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses. Proc. Natl Acad. Sci. USA108(23), 9560–9565 (2011).
   PubMed Web of Science ®Google Scholar
• Schmechel S, Konrad A, Diegelmann J et al. Linking genetic susceptibility to Crohn’s disease with Th17 cell function: IL-22 serum levels are increased in Crohn’s disease and correlate with disease activity and IL23R genotype status. Inflamm. Bowel Dis.14(2), 204–212 (2008).
   PubMed Web of Science ®Google Scholar
• Jurgens M, Laubender RP, Hartl F et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am. J. Gastroenterol.105(8), 1811–1819 (2010).
   PubMed Web of Science ®Google Scholar
• Cargill M, Schrodi SJ, Chang M et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet.80(2), 273–290 (2007).
   PubMed Web of Science ®Google Scholar
• Burton PR, Clayton DG, Cardon LR et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat. Genet.39(11), 1329–1337 (2007).
   PubMed Web of Science ®Google Scholar
• Franke A, McGovern DP, Barrett JC et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat. Genet.42(12), 1118–1125 (2010).
   PubMed Web of Science ®Google Scholar
• Arisawa T, Tahara T, Shibata T et al. The influence of polymorphisms of interleukin-17A and interleukin-17F genes on the susceptibility to ulcerative colitis. J. Clin. Immunol.28(1), 44–49 (2008).
   PubMed Web of Science ®Google Scholar
• Chen B, Zeng Z, Hou J, Chen M, Gao X, Hu P. Association of interleukin-17F 7488 single nucleotide polymorphism and inflammatory bowel disease in the Chinese population. Scand. J. Gastroenterol.44(6), 720–726 (2009).
   PubMed Web of Science ®Google Scholar
• Seiderer J, Elben I, Diegelmann J et al. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn’s disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm. Bowel Dis.14(4), 437–445 (2008).
   PubMed Web of Science ®Google Scholar
• Schmidt C, Giese T, Ludwig B et al. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn’s disease but not in ulcerative colitis. Inflamm. Bowel Dis.11(1), 16–23 (2005).
   PubMed Web of Science ®Google Scholar
• Fuss IJ, Becker C, Yang Z et al. Both IL-12p70 and IL-23 are synthesized during active Crohn’s disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm. Bowel Dis.12(1), 9–15 (2006).
   PubMed Web of Science ®Google Scholar
• Holtta V, Klemetti P, Sipponen T et al. IL-23/IL-17 immunity as a hallmark of Crohn’s disease. Inflamm. Bowel Dis.14(9), 1175–1184 (2008).
   PubMed Web of Science ®Google Scholar
• Fujino S, Andoh A, Bamba S et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut52(1), 65–70 (2003).
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Kirman I, Rudiger N, Hendel J, Vainer B. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand. J. Gastroenterol.38(2), 180–185 (2003).
   PubMedGoogle Scholar
• Kobayashi T, Okamoto S, Hisamatsu T et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease. Gut57(12), 1682–1689 (2008).
   PubMed Web of Science ®Google Scholar
• Kaser A, Ludwiczek O, Holzmann S et al. Increased expression of CCL20 in human inflammatory bowel disease. J. Clin. Immunol.24(1), 74–85 (2004).
   PubMed Web of Science ®Google Scholar
• Brand S, Olszak T, Beigel F et al. Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells. J. Cell. Biochem.97(4), 709–723 (2006).
   PubMedGoogle Scholar
• Talley NJ, Abreu MT, Achkar JP et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am. J. Gastroenterol.106(Suppl. 1), S2–S25 (2011).
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S et al.; for the Secukinumab in Crohn’s Disease Study Group. Secukinumab, a human anti-IL17A monoclonal antibody, for moderate to severe Crohn’s disease: randomized, double-blind placebo controlled trial. Gut (2012) (In Press).
   PubMedGoogle Scholar
• Hu Y, Shen F, Crellin NK, Ouyang W. The IL-17 pathway as a major therapeutic target in autoimmune diseases. Ann. NY Acad. Sci.1217, 60–76 (2011).
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Vandemeulebroecke M et al. Inhibition of IL-17A by secukinumab is ineffective for Crohn’s disease (CD). Presented at: 6th ECCO Congress. Dublin, Ireland, 24–26 February 2011.
   Google Scholar
• Noguchi D, Wakita D, Tajima M et al. Blocking of IL-6 signaling pathway prevents CD4+ T cell-mediated colitis in a T(h)17-independent manner. Int. Immunol.19(12), 1431–1440 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zheng M, Bindas J, Schwarzenberger P, Kolls JK. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm. Bowel Dis.12(5), 382–388 (2006).
   PubMed Web of Science ®Google Scholar